日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection

急性 HIV 感染者接受抗逆转录病毒治疗后一年内会出现抗 HIV 抗体

Julie L Mitchell, Justin Pollara, Kenneth Dietze, R Whitney Edwards, Junsuke Nohara, Kombo F N'guessan, Michelle Zemil, Supranee Buranapraditkun, Hiroshi Takata, Yifan Li, Roshell Muir, Eugene Kroon, Suteeraporn Pinyakorn, Shalini Jha, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantiwora

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy

痰液中结核分枝杆菌mRNA作为抗结核治疗后细菌清除的标志物

Li, L; Mahan, C S; Palaci, M; Horter, L; Loeffelholz, L; Johnson, J L; Dietze, R; Debanne, S M; Joloba, M L; Okwera, A; Boom, W H; Eisenach, K D

Presence of intestinal helminths decreases T helper type 1 responses in tuberculoid leprosy patients and may increase the risk for multi-bacillary leprosy

肠道蠕虫的存在会降低结核样麻风患者的1型辅助性T细胞反应,并可能增加多菌型麻风的风险。

Diniz, L M; Magalhães, E F L; Pereira, F E L; Dietze, R; Ribeiro-Rodrigues, R

Evaluation of low-colony-number counts of Mycobacterium tuberculosis on solid media as a microbiological marker of cross-contamination

评估结核分枝杆菌在固体培养基上的低菌落数作为交叉污染的微生物学标志物

Ribeiro, F K C; Lemos, E M; Hadad, D J; Leão, S C; Viana-Niero, C; Dietze, R; Johnson, J L; Eisenach, K D; Palaci, M

Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy.

肠道蠕虫合并感染会对结核分枝杆菌的免疫力和结核病治疗的临床反应产生负面影响

Resende Co T, Hirsch C S, Toossi Z, Dietze R, Ribeiro-Rodrigues R

A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis

CD4+CD25+ T细胞在人类结核病免疫反应调节中的作用

Ribeiro-Rodrigues, R; Resende Co, T; Rojas, R; Toossi, Z; Dietze, R; Boom, W H; Maciel, E; Hirsch, C S

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

抑制异烟肼诱导的痰液中结核分枝杆菌抗原85的表达:结核病化疗试验中的潜在替代标志物

Wallis, R S; Phillips, M; Johnson, J L; Teixeira, L; Rocha, L M; Maciel, E; Rose, L; Wells, C; Palaci, M; Dietze, R; Eisenach, K; Ellner, J J

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.

利法拉嗪在肺结核患者中的安全性和杀菌活性

Dietze R, Teixeira L, Rocha L M, Palaci M, Johnson J L, Wells C, Rose L, Eisenach K, Ellner J J

Predicting the outcome of therapy for pulmonary tuberculosis

预测肺结核治疗结果

Wallis, R S; Perkins, M D; Phillips, M; Joloba, M; Namale, A; Johnson, J L; Whalen, C C; Teixeira, L; Demchuk, B; Dietze, R; Mugerwa, R D; Eisenach, K; Ellner, J J

Drug tolerance in Mycobacterium tuberculosis

结核分枝杆菌的耐药性

Wallis, R S; Patil, S; Cheon, S H; Edmonds, K; Phillips, M; Perkins, M D; Joloba, M; Namale, A; Johnson, J L; Teixeira, L; Dietze, R; Siddiqi, S; Mugerwa, R D; Eisenach, K; Ellner, J J